Evogene (NASDAQ:EVGN)

Executive Summary

Evogene Ltd. is a publicly traded Israeli company leveraging its proprietary ChemPass AI™ generative AI engine to design novel small-molecule candidates for pharmaceutical and agricultural applications. By optimizing potency, safety, and developability in silico, the platform aims to accelerate discovery and improve success rates. Founded in 2002, the company has raised over $150M and employs 200-500 people. With a focus on both therapeutics and crop protection, Evogene’s platform approach positions it to generate multiple candidates across various programs. However, the company remains in the platform stage with no approved products, and its success depends on advancing its own pipeline and securing value-driving partnerships. The conviction score reflects the potential of its AI technology balanced against the early-stage nature and execution risks in drug development and agricultural markets.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new pharmaceutical or agricultural collaboration leveraging ChemPass AI50% success
• Q3 2026Preclinical data readout or nomination of a lead candidate from an internal program40% success
• Q3 2026Quarterly earnings report providing pipeline update and strategic outlook90% success